AP2695A - Vaccine adjuvants - Google Patents

Vaccine adjuvants

Info

Publication number
AP2695A
AP2695A AP2008004362A AP2008004362A AP2695A AP 2695 A AP2695 A AP 2695A AP 2008004362 A AP2008004362 A AP 2008004362A AP 2008004362 A AP2008004362 A AP 2008004362A AP 2695 A AP2695 A AP 2695A
Authority
AP
ARIPO
Prior art keywords
vaccine adjuvants
vaccine
adjuvants
Prior art date
Application number
AP2008004362A
Other languages
English (en)
Inventor
Nirvai Desai
Prasanta Kumar Ghosh
Bakulesh Mafatlal Khamar
Original Assignee
Cadila Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Pharmaceuticals Ltd filed Critical Cadila Pharmaceuticals Ltd
Application granted granted Critical
Publication of AP2695A publication Critical patent/AP2695A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2008004362A 2005-04-25 2006-04-21 Vaccine adjuvants AP2695A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN505MU2005 2005-04-25

Publications (1)

Publication Number Publication Date
AP2695A true AP2695A (en) 2013-07-16

Family

ID=37215117

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004362A AP2695A (en) 2005-04-25 2006-04-21 Vaccine adjuvants

Country Status (10)

Country Link
US (2) US8048434B2 (fr)
EP (1) EP1948782B8 (fr)
AP (1) AP2695A (fr)
AU (1) AU2006238906B2 (fr)
CA (1) CA2632353C (fr)
EA (1) EA200800917A1 (fr)
ES (1) ES2388684T3 (fr)
GB (1) GB2442408B (fr)
PL (1) PL1948782T3 (fr)
WO (1) WO2006114680A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008269427A1 (en) * 2007-06-28 2008-12-31 Cadila Pharmaceuticals Ltd. Mitogen activated protein kinase modulator
WO2011083493A1 (fr) * 2010-01-08 2011-07-14 National Institute Of Immunology Vaccin à base de gonadotrophine chorionique humaine (hcg) pour la prévention et le traitement du cancer
CN102753975B (zh) * 2010-02-19 2015-05-20 卡帝拉药物有限公司 基本上保留免疫原性的被杀死细胞的药物组合物
US20180042850A1 (en) * 2010-02-19 2018-02-15 Cadila Pharmaceuticals Ltd. Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity
CA2828401C (fr) * 2011-02-28 2023-01-10 Cadila Pharmaceuticals Limited Vaccin therapeutique contre le cancer
ES2647768T3 (es) * 2011-07-05 2017-12-26 Cadila Pharmaceuticals Limited Antígeno de cáncer
WO2020115161A1 (fr) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant destiné à être utilisé contre des pathogènes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049667A2 (fr) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar Methode de traitement du cancer
WO2003075825A2 (fr) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Procede applicable au traitement de la tuberculose

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US6355256B1 (en) 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides
SE9501067D0 (sv) 1995-03-24 1995-03-24 Astra Ab New peptides
JP4104186B2 (ja) 1995-11-30 2008-06-18 財団法人化学及血清療法研究所 オイルアジュバントワクチンおよびその調製方法
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
CU22629A1 (es) 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
JPH11106351A (ja) 1997-10-02 1999-04-20 Chemo Sero Therapeut Res Inst オイルアジュバントワクチンおよびその製造方法
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
JP2001131087A (ja) 1999-11-05 2001-05-15 Chemo Sero Therapeut Res Inst オイルアジュバントワクチン
EP1368044B1 (fr) * 2001-01-17 2009-03-18 Mafatlal Khamar Bakulesh Immunomodulateur de gestion therapeutique de l'infection/maladie de l'immunodeficience humaine (vih)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049667A2 (fr) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar Methode de traitement du cancer
WO2003075825A2 (fr) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Procede applicable au traitement de la tuberculose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORMUS BOBBY J ET AL: "Under-explored experimental topics related to integral mycobacterial vaccines for leprosy" EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 2, no. 6, 1 December 2003 (2003-12-01), pages 791-804, XP009115719 ISSN: 1476-0584 *
PETROVSKY N.: 'Vaccine Adjuvants: Current State and Future Trends' IMMUNOLOGY AND CELL BIOLOGY vol. 82, 2004, pages 488 - 496, XP009078668 *
STILLS HAROLD F JR: "Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants" ILAR JOURNAL, vol. 46, no. 3, 1 January 2005 (2005-01-01), pages 280-293, XP001539142 ISSN: 1084-2020 *

Also Published As

Publication number Publication date
GB2442408A (en) 2008-04-02
EP1948782B8 (fr) 2012-09-12
WO2006114680A3 (fr) 2007-08-23
GB2442408B (en) 2010-06-30
EP1948782A4 (fr) 2009-06-17
EA200800917A1 (ru) 2008-12-30
EP1948782A2 (fr) 2008-07-30
ES2388684T3 (es) 2012-10-17
CA2632353A1 (fr) 2006-11-02
WO2006114680A2 (fr) 2006-11-02
WO2006114680A8 (fr) 2008-08-14
PL1948782T3 (pl) 2013-01-31
US8277778B2 (en) 2012-10-02
AU2006238906A1 (en) 2006-11-02
US20080131458A1 (en) 2008-06-05
AU2006238906B2 (en) 2013-04-11
CA2632353C (fr) 2018-02-20
US8048434B2 (en) 2011-11-01
GB0801474D0 (en) 2008-03-05
EP1948782B1 (fr) 2012-08-01
US20120014985A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0417494D0 (en) Vaccine
GB0409940D0 (en) Vaccine
GB0411150D0 (en) Vaccine
GB0801474D0 (en) Vaccine adjuvants
ZA200709207B (en) Vaccine
GB0519161D0 (en) Adjuvanted vaccine
GB0413510D0 (en) Vaccine
GB0810662D0 (en) Vaccine
GB0515135D0 (en) Vaccine
GB2443591B (en) Adjuvanted vaccine
GB0516944D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0412407D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0526412D0 (en) Vaccine
GB0419838D0 (en) Vaccine adjuvants
GB0526232D0 (en) Vaccine
GB0511475D0 (en) Vaccine
IL186591A0 (en) Vaccine
GB0503000D0 (en) Anti-atheroma vaccine
GB0514021D0 (en) Vaccine
GB0513194D0 (en) Vaccine